Employee Voices

At Novelion Therapeutics, and our subsidiary Aegerion Pharmaceuticals, we seek to develop new standards of care for individuals living with rare diseases. We depend on the commitment, ideas and actions of each individual employee to advance patient care and a create sustainable future for our organization.

Andres video

Andrés Treviño

Senior Director, Government Affairs, Aegerion Pharmaceuticals

Development Pipeline

Our Pipeline: Status of Selected Key Development Programs as of November 2016; represents ongoing phase of development; does not correspond to initiation or completion of a particular phase.

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

Aegerion Products

JUXTAPID® (lomitapide)*
homozygous familial hypercholesterolemia (HoFH) in adults
MYALEPT® (metreleptin)**
generalized lipodystrophy (GL)
metreleptin
partial lipodystrophy (PL)***

Novelion Products

zuretinol
leber congenital amaurosis (LCA)
zuretinol
retinitis pigmentosa (RP)

* Click here for JUXTAPID® (lomitapide) full US prescribing information, including BOXED WARNING for the risk of hepatotoxicity.

** Click here for MYALEPT® (metreleptin) full US prescribing information, including BOXED WARNING for the risk of anti-metreleptin antibodies with neutralizing activity and risk of lymphoma.

*** Plan to submit MAA for metreleptin in EU to treat GL and a subset of PL

Recent Press Releases